Light of DNA-alkylating agents in castration-resistant prostate cancer cells: a novel mixed EGFR/DNA targeting...

Area of Science:

• Proteomics
• Cancer Biology
• Molecular Oncology

Background:

• Prostate cancer (PCa) remains a significant health concern, with ongoing research into novel therapeutic strategies.
• The precise mechanisms of action for novel anti-cancer agents like combi-molecule JDF12 are not fully elucidated.
• Understanding the proteomic alterations induced by JDF12 is crucial for optimizing its therapeutic application.

Purpose of the Study:

• To investigate the proteomic profile of DU145 prostate cancer cells following treatment with combi-molecule JDF12.
• To compare the proteomic changes induced by JDF12 with those caused by Iressa and untreated controls.
• To elucidate the molecular mechanisms underlying JDF12's therapeutic effects on prostate cancer.

Main Methods:

• Cell viability was assessed using MTT assays.
• Apoptosis and cell cycle progression were analyzed via DAPI staining and flow cytometry, respectively.
• Quantitative proteomic analysis was performed using iTRAQ, with selected protein expression validated by qPCR.

Main Results:

• JDF12 significantly inhibited DU145 cell proliferation and enhanced apoptosis compared to Iressa and untreated cells.
• Proteomic analysis identified 42 differentially expressed proteins (21 up-regulated, 21 down-regulated) in JDF12-treated cells.
• Up-regulated proteins were primarily associated with DNA damage/repair and energy metabolism, while down-regulated proteins were linked to apoptosis.

Conclusions:

• The study reveals the proteomic landscape altered by JDF12 in prostate cancer cells, highlighting its role in DNA damage and apoptosis pathways.
• These findings provide insights into the molecular mechanisms of DNA alkylating agents combined with EGFR-blockers for PCa therapy.
• The results suggest potential for expanded clinical applications of DNA alkylating agents and JDF12 in prostate cancer treatment.